NKY(SZ:300109) Sou Hu Cai Jing·2025-04-11 09:20Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Xin Kai Yuan, a company in the chemical products and precision medical industry, with a current stock price of 14.92 yuan and a market capitalization of 7.232 billion yuan [1][2] - Xin Kai Yuan's rolling price-to-earnings (PE) ratio stands at 18.11, significantly lower than the industry average PE of 50.88 and the median PE of 35.81, indicating a relatively undervalued position within its sector [1][2] - As of March 31, 2025, Xin Kai Yuan has 22,700 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder, reflecting a decrease of 1,100 shareholders since the last report [1] Group 2 - The latest financial results for Xin Kai Yuan show a revenue of 1.111 billion yuan for the third quarter of 2024, representing a year-on-year decline of 7.92%, while net profit decreased by 23.13% to 311 million yuan, with a gross profit margin of 52.10% [1] - The company's main business segments include fine chemicals and precision medicine, with key products such as PVPK30, PVP-I, and various diagnostic services, indicating a diverse product portfolio [1]